证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-044 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 申请事项：临床试验 受 理 号：CXHL2500052 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 1 月 9 日受理的 HRS-9813 胶囊临床试验申请符合药品注册的有关要求，同意 本品开展特发性肺纤维化（IPF）的临床试验。 二、药物的其他情况 HRS-9813 胶囊为公司自主研发的 1 类创新药。临床前数据显示，HRS-9813 可显著改善小鼠肺功能和肺纤维化，且安全性良好。经查询，目前国内外尚无同 类药物获批上市。截至目前，HRS-9813 相关项目累计研发投入约为 9,827 万元。 三、风险提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司广东恒瑞医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发关于 HRS-9813 胶囊的《药物临床试验批准通知书》，将于近期开展 ...

Core Viewpoint - In 2024, Heng Rui Medicine achieved significant revenue growth, with total revenue reaching 27.985 billion yuan, a year-on-year increase of 22.63%, and net profit attributable to shareholders reaching 6.337 billion yuan, up 47.28% year-on-year, indicating a potential shift from "supply chain disruption" to "turnaround" [1][6]. Group 1: Performance Drivers - The strong performance in 2024 is primarily driven by substantial external licensing income, including 1.6 billion euros from Merck Healthcare and 1 billion USD from Kailera Therapeutics, leading to a sixfold increase in licensing income compared to 2023 [7][12]. - The company's core business net profit and non-recurring net profit would revert to around 4 billion yuan if excluding these non-recurring gains, indicating reliance on external partnerships for profit growth [7][15]. Group 2: Impact of Centralized Procurement - The generic drug business still contributes 50% to the company's revenue, and the impact of centralized procurement remains significant, with ongoing effects from previous rounds of procurement [3][4]. - The third and fifth rounds of centralized procurement led to substantial revenue declines in 2021, with sales dropping by 55% and 37% respectively for affected products [3][4]. - The seventh round of procurement also saw a 48% decline in sales for affected products, and the upcoming ninth round is expected to further impact revenue in 2025 [5][6]. Group 3: Valuation and Investment Considerations - The current rolling P/E ratio of around 50 suggests that the company may need 2-3 years to digest this valuation, with expectations of net profit growth slowing to 15%-20% from 2025 to 2027 [17][18]. - The market is shifting focus from short-term profits to long-term innovation value, which may limit the short-term upside for Heng Rui Medicine, given its significant reliance on generic drugs [20].

Summary of the Conference Call for 恒瑞医药 (Hengrui Medicine) Company Overview - **Company**: 恒瑞医药 (Hengrui Medicine) - **Fiscal Year**: 2024 - **Revenue**: 27.9 billion RMB, a 22% increase year-on-year [3][5][29] Key Financial Performance - **Revenue Breakdown**: - Innovative drug sales increased by 30%, accounting for over 50% of total product sales [3][5] - Licensing income confirmed at 2.7 billion RMB, with significant contributions from partnerships with Merck and Calithera [3][7] - **Total Costs**: 21 billion RMB, a 15% increase, primarily due to rising sales and R&D expenses [3] - **Net Profit**: 6.3 billion RMB, a 47% increase, driven by growth in innovative drug sales and licensing income [3] Innovation and R&D - **Innovative Drug Pipeline**: - 19 first-class and 4 second-class innovative drugs approved for market [3][5] - Over 90 self-innovated products in clinical stages, with approximately 400 clinical trials ongoing [3][5] - **R&D Investment**: - R&D spending exceeded 8 billion RMB, representing over 30% of sales, aiming to reduce this ratio to around 20% in the future [3][22] - Focus on improving R&D efficiency while maintaining necessary funding for over 300 clinical trials [22] Internationalization Strategy - **Global Expansion**: - Achieved breakthroughs in internationalization, including three first-generic qualifications in the U.S. [3][5] - Plans to issue shares in Hong Kong to diversify funding sources and enhance international brand image [6] - **Collaborations**: - Engaged in partnerships with leading global pharmaceutical companies, prioritizing collaborations that retain domestic development rights [6][30] Sales and Marketing - **Sales Expense Trends**: - Sales expense ratio has been decreasing due to increased BDI income, expected to remain within a reasonable range [3][10] - **Market Positioning**: - Focus on innovative drugs while managing the impact of centralized procurement policies on generic drug sales [29] Regulatory and Tax Considerations - **Tax Rate Changes**: - Increased effective tax rate due to rising R&D expenses and inability to fully offset losses with profits [31] - **Impact of VAT Adjustments**: - Monitoring the implications of VAT changes on financial performance, with no immediate adjustments required for current products [15][17] Future Outlook - **Growth Projections**: - Anticipated growth in innovative drug sales exceeding 26% over the next two to three years, while generic drug growth remains uncertain due to policy impacts [29] - **BD Strategy**: - Plans to expand BD transactions, focusing on early-stage products to recover R&D costs and mitigate risks [12][30] Additional Insights - **Clinical Research Developments**: - Positive data from multiple clinical trials, including advancements in ADC platforms and dual-specific antibodies [20][33] - **Market Competitiveness**: - Strategies in HR-positive breast cancer treatment and the development of new CDK inhibitors to enhance patient outcomes [24][25] This summary encapsulates the key points from the conference call, highlighting the financial performance, innovation strategies, internationalization efforts, and future growth outlook for 恒瑞医药.

Core Viewpoint - Heng Rui Medicine (600276.SH) achieved record high revenue and net profit driven by innovative drugs, with a significant stock price increase recently [1][2][3] Financial Performance - In 2024, Heng Rui Medicine reported revenue of 27.985 billion yuan, a year-on-year increase of 22.63%, and a net profit of 6.337 billion yuan, up 47.28% year-on-year [1] - The company's innovative drug sales revenue reached 13.892 billion yuan, contributing over half of total sales revenue, with a year-on-year growth of 30.60% [3][4] Research and Development - Heng Rui Medicine's R&D investment reached a historical high of 8.228 billion yuan in 2024, representing a year-on-year increase of 33.79%, accounting for 29.40% of revenue [1][4] - Cumulatively, the company has invested over 44 billion yuan in R&D to date [1] Innovation and Product Development - The company expects over 40 innovative products to be approved for market in the next three years, covering various therapeutic areas including oncology and cardiovascular diseases [7][9] - In 2024, 10 innovative products were approved, including four first-class innovative drugs [7][8] Internationalization and Business Development - Heng Rui Medicine has initiated over 20 overseas clinical trials in countries such as the US, Europe, and Japan, with several products entering Phase III trials [11][12] - The company has engaged in 13 licensing transactions with global partners, with a potential total transaction value of approximately 14 billion USD [12][13]

3月31日，公募基金2024年年报基本披露完毕。 天相投顾数据显示，上市公司业绩成为公募基金买入的"锚"，在2024年公募基金净买入金额前十个股 中，美的集团、比亚迪等绩优股频现。红利资产也成为公募基金的"心头好"，格力电器、中国平安、长 江电力、京沪高铁、招商银行等也被公募基金大手笔买入。 数据显示，美的集团、格力电器、宁德时代、比亚迪、立讯精密等在2024年被公募基金净买入金额居 前；贵州茅台、恒瑞医药、长安汽车、泸州老窖、陕西煤业等遭公募基金净卖出金额居前。 ● 本报记者 万宇 张凌之 锚定绩优股 2024年，公募基金净买入金额较多的公司集中在家电、新能源等领域的绩优公司，以及金融、能源等领 域的红利资产。 天相投顾数据显示，2024年全年，公募基金净买入金额前十的个股为美的集团、格力电器、宁德时代、 比亚迪、立讯精密、中国平安、长江电力、赛力斯、京沪高铁、招商银行。 具体来看，美的集团2024全年获公募基金净买入208.26亿元，位居榜首；格力电器获公募基金净买入 132.46亿元，位居次席；宁德时代、比亚迪获公募基金净买入金额均超100亿元；立讯精密、中国平 安、长江电力、赛力斯、京沪高铁、招商银行 ...

最近权益市场下跌的逻辑比较清晰，美股上周三盘中开始传汽车关税要落地，并且周三盘后正式 签署了行政命令，同时签署的时候明确表示 对等关税4月2日生效 ，然后美股上周三开始连跌三 天，纳指跌超5%，而黄金开始连涨，现货黄金从3000美刀的位置， 以每天1%的速度向上突破， 今天上午突破了3100美刀，继续历史新高。 市场的避险情绪很明确，且可能一直到4月2日前后都是这么个环境，这里提到的4月2日，是美国 东部时间的白天，换算过来，就是我们4月3日，也就是周四的凌晨或者上午，所以，对A股和H 股的冲击，理论上会延续到周四。 今天A股和H股都算很顽强了，下午拉起来后，恒生指数跌1%出头，wind全A跌不到1%，而海外 一片狼藉，特别是亚太地区，日本跌超4%、韩国跌超3%、中国台湾跌超4%，欧洲那边跌幅也不 小，而美股纳指期货目前也跌超1%，纳指可能今晚会创年内的新低。 过程中，等待机会吧， 看看能不能等到A股3300点以下的筹码 。 ...... 聊一下大行5000亿的注资吧 ，今天，获得定增的四家， 建行、中行、交行、邮储 ，今天涨幅分 别是3.64%、1.82%、1.22%、0.19%，而银行指数涨幅0.35%， ...

Investment Rating - The investment rating for the company is "Accumulate-A" with a target price of 55.58 CNY for the next six months [3]. Core Views - The company reported a revenue of 27.985 billion CNY for 2024, representing a year-on-year growth of 22.63%, and a net profit of 6.337 billion CNY, up 47.28% year-on-year. The sales revenue from innovative drugs reached 13.892 billion CNY, growing by 30.60% year-on-year [1][2]. - The company has made significant progress in overseas business development (BD), achieving approximately 8 cooperation agreements since 2023, which are expected to enhance its international market presence and valuation [1][2]. - The company anticipates that 11 projects will be approved for market launch in 2025, 13 in 2026, and 23 in 2027, which are expected to drive revenue growth from innovative drugs [7]. Financial Summary - The projected revenues for 2025, 2026, and 2027 are 31.216 billion CNY, 35.320 billion CNY, and 39.863 billion CNY, respectively. The corresponding net profits are expected to be 7.091 billion CNY, 8.143 billion CNY, and 9.363 billion CNY [7][9]. - The earnings per share (EPS) for the same years are projected to be 1.11 CNY, 1.28 CNY, and 1.47 CNY, with price-to-earnings (PE) ratios of 43.7, 38.1, and 33.1, respectively [7][9]. - The company’s net profit margin is expected to improve from 22.6% in 2024 to 23.5% in 2027, indicating a positive trend in profitability [9][11].

金融界3月31日消息，上证指数下跌0.46%，中国战略新兴产业成份指数 (新兴成指，000171)下跌 0.7%，报1209.46点，成交额797.64亿元。 从中国战略新兴产业成份指数持仓的市场板块来看，深圳证券交易所占比60.96%、上海证券交易所占 比39.04%。 从中国战略新兴产业成份指数持仓样本的行业来看，信息技术占比27.54%、工业占比19.46%、通信服 务占比14.09%、医药卫生占比13.75%、可选消费占比9.87%、金融占比8.16%、原材料占比6.52%、公用 事业占比0.31%、主要消费占比0.29%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样 本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 跟踪新兴成指的公募基金包括：华夏战略新兴成指ETF联接A、华夏战略新兴成指ETF联接C、华夏战略 新兴成指ETF。 数据统计显示 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-042 江苏恒瑞医药股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的《药品注册证书》，批准公司自 主研发的 1 类创新药硫酸艾玛昔替尼片（SHR0302 片）新增适应症，用于对一种 或多种 TNF 抑制剂疗效不佳或不耐受的中重度活动性类风湿关节炎成人患者。现 将相关情况公告如下： 一、 药品的基本情况 审批结论：根据《中华人民共和国药品管理办法》及有关规定，经审查，本 品符合药品注册的有关要求，批准新增适应症，发给药品注册证书。批准的适应 症为"本品适用于对一种或多种 TNF 抑制剂疗效不佳或不耐受的中重度活动性类 风湿关节炎成人患者"。 二、 药品的其他情况 药品名称：硫酸艾玛昔替尼片 剂型：片剂 规格：4mg 注册分类：化学药品 1 类 受理号：CXHS2300108 处方药/非处方药：处方药 类风湿关节炎 ...

Summary of Key Points from the Conference Call Industry Overview - The conference call primarily discusses the **pharmaceutical industry** and the **innovative drug sector** in China for the year 2025, highlighting various trends, opportunities, and challenges within the sector [2][4][26]. Core Insights and Arguments - **Policy Support for Innovative Drugs**: The Chinese government has approved a comprehensive plan to support innovative drug development, which includes price management, medical insurance payments, and diversified payment systems. This is expected to accelerate drug approval processes and enhance market opportunities for innovative drugs [2][3]. - **High Growth Potential**: The innovative drug sector is anticipated to maintain a high growth trajectory due to favorable policies and ongoing medical insurance negotiations. Companies like BeiGene and Hengrui Medicine are expected to benefit significantly from these developments [2][4]. - **AI in Healthcare**: The rapid development of AI in healthcare is highlighted, with companies that possess high-quality data expected to lead in AI applications for diagnostics and health management [2][5]. - **Medical Device Sector Recovery**: The medical device sector is showing signs of marginal recovery, particularly in the ophthalmology segment, driven by favorable fertility policies and increased demand for refractive surgeries [2][6]. - **Global Competitiveness of Chinese Firms**: Chinese innovative drug companies are increasingly demonstrating global competitiveness, with a significant share of global upfront payments and R&D milestones [2][8]. - **Transformation of Traditional Pharmaceutical Companies**: Traditional pharmaceutical companies are accelerating their transformation, with a focus on differentiated innovative products. Companies like East China Pharmaceutical and China National Pharmaceutical Group are noted for their promising prospects [2][9]. - **CXO Sector Recovery**: The CXO sector is gradually recovering, with leading companies like WuXi AppTec showing strong fundamentals and rapid order growth [2][27]. - **Technological Innovation in Medical Devices**: The medical device sector is characterized by strong technological innovation, with companies like United Imaging Healthcare expected to achieve significant growth in 2025 [2][38]. Notable Companies and Investment Opportunities - **Recommended Companies**: Key companies to watch include BeiGene, Hengrui Medicine, and Innovent Biologics in the innovative drug space, and United Imaging Healthcare in the medical device sector. These companies are recognized for their differentiated competitive advantages and potential for international expansion [2][7][12]. - **BeiGene's Profitability**: BeiGene is projected to achieve profitability in 2025, with its leading product, Zanubrutinib, expected to continue strong sales growth in the U.S. market [10][11]. - **Hengrui Medicine's Internationalization**: Hengrui is making significant strides in international markets, with a robust pipeline and expected high growth rates [12][15]. - **Innovent Biologics' Breakthroughs**: Innovent is noted for its advancements in tumor immunotherapy, with promising data expected from its overseas trials [16][19]. - **East China Pharmaceutical's Growth**: East China Pharmaceutical is positioned for growth with a diverse pipeline and strong market presence [24][25]. Additional Important Insights - **Market Trends**: The overall pharmaceutical market is expected to see a recovery in 2025, with innovative drugs leading the way due to supportive policies and market dynamics [4][26]. - **Investment Sentiment**: There is a positive sentiment towards the pharmaceutical sector, with expectations of continued growth driven by innovation and policy support [2][26]. - **Challenges and Risks**: While the outlook is positive, potential risks include regulatory changes and market competition, which could impact the performance of certain companies [2][3][4]. This summary encapsulates the key points discussed in the conference call, providing a comprehensive overview of the pharmaceutical industry's current landscape and future prospects.